How the 13-lined ground squirrel led an East Bay company to a potential half-billion-dollar drug deal

The Emeryville company is building out its own pipeline of potential drugs, including programs in lung-scarring pulmonary fibrosis and the genetic blinding disease retinitis pigmentosa.
Click here to view original post

Advertisement — Advertise with Biotech Networks